Fox Run Management L.L.C. Buys Shares of 23,839 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fox Run Management L.L.C. bought a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 23,839 shares of the biopharmaceutical company’s stock, valued at approximately $783,000.

Other hedge funds have also recently made changes to their positions in the company. State Street Corp grew its position in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $33,767,000. BNP Paribas Financial Markets lifted its stake in shares of Agios Pharmaceuticals by 15.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 1,570 shares during the last quarter. FMR LLC lifted its stake in shares of Agios Pharmaceuticals by 283.2% in the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock valued at $2,017,000 after acquiring an additional 33,546 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in Agios Pharmaceuticals during the 3rd quarter valued at approximately $892,000.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $31.30 on Monday. Agios Pharmaceuticals, Inc. has a one year low of $27.14 and a one year high of $62.58. The stock’s fifty day moving average is $33.38 and its 200 day moving average is $41.28. The stock has a market cap of $1.79 billion, a P/E ratio of 2.76 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on AGIO shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Finally, Scotiabank increased their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.